Study ID	Intervention and comparator	% women	Age (mean/range years (SD))	Comedications / Cointerventions / Comorbidities
Albino 2010	I1: 0.1 mg rhTSH + radioiodine (1.11 GBq)	88	62 (44 to 74)	All participants were advised to follow a low‐iodine diet, starting 2 weeks prior to the administration of the diagnostic and therapeutic activities of radioiodine
	I2: 0.01 mg rhTSH + radioiodine (1.11 GBq)	100	61 (52 to 72)
	C: placebo and radioiodine (1.11 GBq)	88	60 (33 to 72)
Bonnema 2007	I: 0.3 mg rhTSH + radioiodine (aiming at a thyroid dose of 100 Gy)	71	57 (42 to 84)	—
	C: isotonic saline + radioiodine (aiming at a thyroid dose of 100 Gy)	80	65 (37 to 87)
Cubas 2009	I1: 0.005 mg rhTSH + radioiodine (1.11 GBq)	100	60 (48 to 73)	None of the participants had serious medical conditions and all of them had subclinical hyperthyroidism (which was treated with methimazole), or were euthyroid
	I2: 0.1 mg rhTSH + radioiodine (1.11 GBq)	100	61 (49 to 73)
	C: placebo and radioiodine (1.11 GBq)	80	62 (45 to 86)
Fast 2010	I: 0.1 mg rhTSH + radioiodine (50 Gy)	83	52 (22 to 83)	—
	C: placebo + radioiodine (100 Gy)	93	55 (27 to 78)	—
Fast 2014	I1: 0.01 mg rhTSH + radioiodine (100 Gy)	97	57.3 (10.2)	—
	I2: 0.03 mg rhTSH + radioiodine (100 Gy)	76	56.9 ± 10.3
	C: placebo and radioiodine (100 Gy)	84	57.5 (8.7)
Nielsen 2006	I: 0.3 mg rhTSH + radioiodine (calculated based on thyroid size, thyroid 131I uptake, and 131I half‐life)	86	52 (32 to 68)	6% of participants had previous thyroidectomy
	C: placebo + radioiodine (calculated based on thyroid size, thyroid 131I uptake, and 131I half‐life)	93	52 (26 to 77)	5% of participants had previous thyroidectomy
—: denotes not reported 131I: radioactive iodine; C: comparator; GBq: giga Becquerel; Gy: Gray; I: intervention; rhTSH: recombinant human thyrotropin; SD: standard deviation